Mendus AB (publ) (IMMU.ST)
SEK 4.94
(-0.2%)
SEK 4.94
(-0.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 129.13 Million SEK | -4.13% |
| 2022 | 134.69 Million SEK | 4.19% |
| 2021 | 129.27 Million SEK | 50.39% |
| 2020 | 85.96 Million SEK | -34.7% |
| 2019 | 131.64 Million SEK | 34.54% |
| 2018 | 97.84 Million SEK | 21.25% |
| 2017 | 80.69 Million SEK | 9.96% |
| 2016 | 73.39 Million SEK | 68.17% |
| 2015 | 43.64 Million SEK | 19.89% |
| 2014 | 36.4 Million SEK | 118.62% |
| 2013 | 16.65 Million SEK | 138.8% |
| 2012 | 6.97 Million SEK | 159.28% |
| 2011 | 2.68 Million SEK | -0.81% |
| 2010 | 2.71 Million SEK | 17.5% |
| 2009 | 2.3 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 36.38 Million SEK | -15.04% |
| 2024 Q2 | 36.64 Million SEK | 4.28% |
| 2023 Q3 | 25.85 Million SEK | -6.79% |
| 2023 Q4 | 42.82 Million SEK | 65.63% |
| 2023 Q2 | 27.73 Million SEK | -6.32% |
| 2023 FY | 123.4 Million SEK | -8.39% |
| 2023 Q1 | 29.6 Million SEK | -26.97% |
| 2022 Q2 | 28.13 Million SEK | -1.68% |
| 2022 Q3 | 37.4 Million SEK | 32.94% |
| 2022 FY | 134.69 Million SEK | 4.19% |
| 2022 Q4 | 40.54 Million SEK | 8.41% |
| 2022 Q1 | 28.61 Million SEK | -7.46% |
| 2021 Q2 | 31.27 Million SEK | -23.3% |
| 2021 Q1 | 40.78 Million SEK | 670.6% |
| 2021 FY | 129.27 Million SEK | 50.39% |
| 2021 Q4 | 30.92 Million SEK | 17.59% |
| 2021 Q3 | 26.29 Million SEK | -15.93% |
| 2020 Q3 | 21.65 Million SEK | -13.92% |
| 2020 Q1 | 33.86 Million SEK | -14.58% |
| 2020 FY | 85.96 Million SEK | -34.7% |
| 2020 Q4 | 5.29 Million SEK | -75.56% |
| 2020 Q2 | 25.15 Million SEK | -25.74% |
| 2019 Q4 | 39.64 Million SEK | 33.76% |
| 2019 Q1 | 29.13 Million SEK | 11.18% |
| 2019 Q2 | 33.21 Million SEK | 13.97% |
| 2019 Q3 | 29.64 Million SEK | -10.74% |
| 2019 FY | 131.64 Million SEK | 34.54% |
| 2018 Q2 | 19.34 Million SEK | -32.75% |
| 2018 FY | 97.84 Million SEK | 21.25% |
| 2018 Q1 | 28.77 Million SEK | 47.88% |
| 2018 Q4 | 26.2 Million SEK | 11.43% |
| 2018 Q3 | 23.52 Million SEK | 21.57% |
| 2017 Q3 | 21.59 Million SEK | 12.99% |
| 2017 Q1 | 20.53 Million SEK | -16.65% |
| 2017 FY | 80.69 Million SEK | 9.96% |
| 2017 Q4 | 19.45 Million SEK | -9.92% |
| 2017 Q2 | 19.11 Million SEK | -6.9% |
| 2016 Q1 | 9.52 Million SEK | -15.13% |
| 2016 FY | 73.39 Million SEK | 68.17% |
| 2016 Q4 | 24.63 Million SEK | 104.98% |
| 2016 Q3 | 12.01 Million SEK | -20.24% |
| 2016 Q2 | 15.06 Million SEK | 58.14% |
| 2015 Q4 | 11.22 Million SEK | 43.57% |
| 2015 Q1 | 10.65 Million SEK | -4.23% |
| 2015 Q2 | 8.23 Million SEK | -22.78% |
| 2015 Q3 | 7.81 Million SEK | -4.99% |
| 2015 FY | 43.64 Million SEK | 19.89% |
| 2014 Q1 | 5.01 Million SEK | 27.68% |
| 2014 FY | 36.4 Million SEK | 118.62% |
| 2014 Q4 | 11.12 Million SEK | 74.22% |
| 2014 Q3 | 6.38 Million SEK | 9.35% |
| 2014 Q2 | 5.84 Million SEK | 16.47% |
| 2013 Q3 | 1.86 Million SEK | -33.13% |
| 2013 FY | 16.65 Million SEK | 138.8% |
| 2013 Q2 | 2.79 Million SEK | 8.55% |
| 2013 Q1 | 2.57 Million SEK | 134.35% |
| 2013 Q4 | 3.92 Million SEK | 110.31% |
| 2012 Q4 | 1.09 Million SEK | -0.0% |
| 2012 Q3 | 1.09 Million SEK | 131.53% |
| 2012 Q2 | 474.21 Thousand SEK | 0.0% |
| 2012 Q1 | 474.21 Thousand SEK | 0.0% |
| 2012 FY | 6.97 Million SEK | 159.28% |
| 2011 FY | 2.68 Million SEK | -0.81% |
| 2010 FY | 2.71 Million SEK | 17.5% |
| 2009 FY | 2.3 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alzinova AB (publ) | 36.39 Million SEK | -254.811% |
| Amniotics AB (publ) | 29.07 Million SEK | -344.197% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -781.301% |
| BioArctic AB (publ) | 89.62 Million SEK | -44.083% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 91.472% |
| Saniona AB (publ) | 1.07 Million SEK | -11890.436% |
| Simris Alg AB (publ) | 38.64 Million SEK | -234.188% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 59.834% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -489.801% |
| NextCell Pharma AB | -576.01 Thousand SEK | 22518.879% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -355.89% |
| AcouSort AB (publ) | 25.87 Million SEK | -399.061% |
| Active Biotech AB (publ) | 44.8 Million SEK | -188.194% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 57.948% |
| Camurus AB (publ) | 1.05 Billion SEK | 87.813% |
| Cantargia AB (publ) | 290.01 Million SEK | 55.473% |
| Genovis AB (publ.) | 88.19 Million SEK | -46.419% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -12.222% |
| Kancera AB (publ) | 63.07 Million SEK | -104.729% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -2239.862% |
| LIDDS AB (publ) | 27.75 Million SEK | -365.325% |
| Lipum AB (publ) | 37.3 Million SEK | -246.147% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1680.218% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 4.985% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -687.373% |
| OncoZenge AB (publ) | 15.9 Million SEK | -711.927% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 63.89% |
| Xintela AB (publ) | 57.31 Million SEK | -125.307% |
| Ziccum AB (publ) | 27.87 Million SEK | -363.222% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1676.789% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 28.942% |
| CombiGene AB (publ) | 44.14 Million SEK | -192.535% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 9.686% |
| Intervacc AB (publ) | 79.78 Million SEK | -61.856% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -202.911% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -630.289% |
| Corline Biomedical AB | 30.16 Million SEK | -328.06% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -122.531% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -55.271% |
| Aptahem AB (publ) | 10.01 Million SEK | -1189.701% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 4.126% |
| Fluicell AB (publ) | 28.61 Million SEK | -351.26% |
| Biovica International AB (publ) | 133.72 Million SEK | 3.429% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -552.537% |
| Abliva AB (publ) | 27.86 Million SEK | -363.421% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 33.263% |
| 2cureX AB (publ) | 36.51 Million SEK | -253.626% |
| I-Tech AB | 40.14 Million SEK | -221.652% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 84.974% |
| Cyxone AB (publ) | 28.21 Million SEK | -357.705% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -18.076% |
| Biosergen AB | 26.8 Million SEK | -381.693% |
| Nanologica AB (publ) | 69.88 Million SEK | -84.78% |
| SynAct Pharma AB | 224.49 Million SEK | 42.477% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -192.324% |
| BioInvent International AB (publ) | 441.4 Million SEK | 70.744% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -439.098% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 55.431% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1543.745% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -16.43% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -778.483% |